10th November 2017, Volume 130 Number 1465

Aimee Staveley, Ian Soosay, Anthony J O’Brien

Characterised by central obesity, dyslipidaemia, hypertension and insulin resistance,1 metabolic syndrome is a major public health issue that affects a diverse range of population groups.2 Compared to the general population,…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Summary

People with mental illness have a 20-year reduction in life expectancy compared to people in the general population. One of the factors contributing to this difference is antipsychotic medication, commonly prescribed for people with severe mental illness. We surveyed the district health boards’ mental health services to investigate their policies for monitoring the physical health of people with severe mental illness. We found that most DHBs had policies for monitoring physical health, but also that there was scope for improvement in those policies. Our recommendation is that the Ministry of Health adopt a best practice standard in this area, and require DHBs to report against this standard.

Abstract

Aim

To audit New Zealand district health boards’ (DHBs) metabolic monitoring policies in relation to consumers prescribed second-generation antipsychotic medications using a best practice guideline.

Method

Metabolic monitoring policies from DHBs and one private clinic were analysed in relation to a best practice standard developed from the current literature and published guidelines relevant to metabolic syndrome.

Results

Fourteen of New Zealand’s 20 DHBs currently have metabolic monitoring policies for consumers prescribed antipsychotic medication. Two of those policies are consistent with the literature-based guideline. Eight policies include actions to be taken when consumers meet criteria for metabolic syndrome. Four DHBs have systems for measuring their rates of metabolic monitoring. There is no consensus on who is clinically responsible for metabolic monitoring.

Conclusion

Metabolic monitoring by mental health services in New Zealand reflects international experience that current levels of monitoring are low and policies are not always in place. Collaboration across the mental health and primary care sectors together with the adoption of a consensus guideline is needed to improve rates of monitoring and reduce current rates of physical health morbidities.

Author Information

Aimee Staveley, Research Student, School of Nursing, University of Auckland, Auckland; 
Ian Soosay, Honorary Academic, Faculty of Medical and Health Sciences, University of Auckland, Auckland; Anthony J O’Brien, Senior Lecturer, School of Nursing, University of Auckland, Auckland.

Acknowledgements

This research was partly funded by a grant from the University of Auckland Faculty of Medical and Health Sciences. We are indebted to the service users and clinicians who advised on various aspects of the research, and to the DHB staff who provided metabolic monitoring policies.

Correspondence

Anthony J O’Brien, Senior Lecturer, School of Nursing, University of Auckland, Private Bag 92019, Auckland.

Correspondence Email

a.obrien@auckland.ac.nz

Competing Interests

Aimee Staveley reports grants from The University of Auckland Faculty of Medical and Health Sciences during the conduct of the study. Dr O'Brien reports summer scholarship from University of Auckland during the conduct of the study.

References

  1. De Hert M, Detraux J, Van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8(2):114–26.
  2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16):1640–5.
  3. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998; 173(1):11–53.
  4. Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 2011; 199(6):441–2.
  5. Cunningham R, Sarfati D, Peterson D, et al. Premature mortality in adults using New Zealand psychiatric services. N Z Med J. 2014; 127(1394).
  6. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five-year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010; 196(2):116–2.
  7. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64(10):1123–31.
  8. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006; 51(8):492–501
  9. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13(2):153–160.
  10. Riordan HJ, Antonini P, Murphy MF. Second generation antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am Health Drug Benefits 2014; 4(5):292.
  11. De Hert M, Dekker J, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24(6):412–24.
  12. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011; 10(1):52–77.
  13. Waterreus AJ, Laugharne J. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust. 2009; 190(4):185–9.
  14. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011; 199(2):99–105.
  15. Barnes TR, Paton C, Cavanagh MR, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007; 33(6):1397–403.
  16. Laugharne J, Waterreus AJ, Castle DJ, Dragovic M. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry. 2016; 24(1):62–6.
  17. New Zealand Mental Health Metabolic Working Group. Intervention guide for mental health service users on antipsychotic therapy. Auckland: Janssen Cilag NZ Ltd. 2008
  18. Galletly C, Castle D, Dark F. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust NZ J Psychiatry 2016; 50(5):1–117.
  19. Cooper SJ, Reynolds GP, Barnes TR, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30(8):717–48.
  20. Ministry of Health (2013). New Zealand Primary Care Handbook 2012 (updated 2013): Cardiovascular Disease Risk Assessment
  21. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust NZ J Psychiatry 2005; 39(6):479–486.
  22. Yarborough BJH, Leo MC, Stumbo S, Perrin NA, Green CA. STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications. BMC Psychiatry 2013; 13(1):238.
  23. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust NZ J Psychiatry 2007; 41(12):980–989.
  24. Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistance in patients receiving second generation antipsychotic agents: a meta-analysis. J Clin Psychiat 2010; 71(10):1286–1292.
  25. Ward T, Wynaden D, Heslop K. Who is responsible for metabolic screening for mental health clients taking antipsychotic medications. Int J Ment Health Nurs. 2017 Epub ahead of print doi: 10.1111/inm.12309
  26. Mitchell A, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012; 42(01):125–47.
  27. Naylor CP, McDaid M, Knapp D, Fossey M, Gallea A. 2012. Long term conditions and mental health: The cost of co-morbidities. London: The Kings Fund. 
  28. Happell B, Stanton R, Platania-Phung C, McKenna B, Scott D. The cardiometabolic health nurse: Physical health behaviour outcomes from a randomised controlled trial. Issues Ment Health Nurs 2014; 35(10):768–775.
  29. Osborn DP, Nazareth I, Wright CA, King MB. Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. BMC Health Serv Res. 2010; 10(1):61.
  30. Coates D, Woodford P, Higgins O, Grover D. (2017). Evaluation of a general practitioner-led cardiometabolic clinic: Physical health profile and treatment outcomes for clients on clozapine. Int J Ment Health Nurs. 2017 Epub ahead of print. doi: 10.1111/inm.12321
  31. Young SJ, Praskova A, Hayward N, Patterson S. (2016). Attending to physical health in mental health services in Australia: a qualitative study of service users’ experiences and expectations. Health Social Care Community 2016; 25(2):605–611.
  32. Robson D, Haddad M, Gray R, Gournay K. Mental health nursing and physical health care: A cross-sectional study of nurses' attitudes, practice, and perceived training needs for the physical health care of people with severe mental illness. Int J Ment Health Nurs 2013; 22(5):409–417.
  33. Improving access to primary care in Tairawhiti. Retrieved 19 May 2017 from www.tepou.co.nz/news/improving-access-to-primary-care-in-tairawhiti/628 
  34. Gentles D, Metcalf P, Dyall L, Sundborn G, Schaaf D, Black P, et al. Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. NZ Med J 2017; (Online) 120(1248).
  35. Ministry of Health. Annual Update of Key Results 2015/16: New Zealand Health Survey; Wellington: Ministry of Health 2016.

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe